Karamedica's Chief Scientific Officer Sam Hudson was recently the plenary speaker at the Polish Chitin Society conference in Olsztyn, Poland, offering a lecture “A Discussion of the Synthesis and Characterization of Chitosan/Plasmid DNA Nanoparticles and Future Challenges.” https://lnkd.in/ehSEC7jp
Karamedica, Inc.
Biotechnology Research
Raleigh, North Carolina 114 followers
Developing a non-viral nose-to-brain delivery platform with nucleic acids or small molecules as therapeutics.
About us
Karamedica is expanding therapeutic uses of biopolymer-based products, including chitosan. Supported by NIH funding, we have developed an early stage non-viral nose-to-brain delivery platform for nucleic acids or small molecules.
- Website
-
http://www.karamedica.com
External link for Karamedica, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Raleigh, North Carolina
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Life Sciences, Therapeutics, Drug Delivery, Gene Delivery, and Biotechnology
Locations
-
Primary
Get directions
310 S Harrington St
Raleigh, North Carolina, US